Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association - PubMed (original) (raw)
Comparative Study
. 2012 Jun;26(6):1247-54.
doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.
N Boissel, O Nibourel, C Berthon, N Helevaut, C Gardin, J-M Cayuela, S Hayette, O Reman, N Contentin, D Bordessoule, C Pautas, S de Botton, T de Revel, C Terre, P Fenaux, X Thomas, S Castaigne, H Dombret, C Preudhomme
Affiliations
- PMID: 22289988
- DOI: 10.1038/leu.2011.382
Comparative Study
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association
A Renneville et al. Leukemia. 2012 Jun.
Abstract
Recently, DNA methyltransferase 3A (DNMT3A) mutations have been identified in acute myeloid leukemia (AML), the highest frequency being found within cytogenetically normal (CN) AML. In this study, diagnostic samples from 123 adults younger than 60 years with primary CN-AML homogeneously treated in the Acute Leukemia French Association-9801 and -9802 trials were screened for mutations in DNMT3A-conserved domains by direct sequencing. Patients were also assessed for the presence of FLT3 (fms-like tyrosine kinase receptor-3), NPM1 (nucleophosmin), CEBPA, WT1 (Wilms tumor 1), IDH1 (isocitrate dehydrogenase 1) and IDH2 mutations. Thirty-eight mutations were detected in 36 patients (29%): 36 nucleotide substitutions, mostly affecting amino-acid residue R882 and two frameshift deletions. DNMT3A mutations were significantly associated with the French-American-British subtypes M4/M5 and the presence of NPM1 mutations. In the whole cohort, DNMT3A mutated patients had a shorter event-free survival (5-year EFS: 13% vs 32%, P = 0.02) and overall survival (5-year OS: 23% vs 45%, P = 0.02) compared with DNMT3A wild-type patients. In multivariate analysis including age, white blood cell count, NPM1/FLT3-internal tandem duplication/CEBPA risk group and DNMT3A mutational status, the presence of a DNMT3A mutation remained an independent adverse prognostic factor for EFS and OS, suggesting that testing for DNMT3A mutations could help further improve risk stratification in CN-AML.
Similar articles
- Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M. Thol F, et al. J Clin Oncol. 2011 Jul 20;29(21):2889-96. doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13. J Clin Oncol. 2011. PMID: 21670448 Clinical Trial. - DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D, Taalab MM, Ghazy HF, Eneen AF. El Ghannam D, et al. Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):61-6. doi: 10.1016/j.bcmd.2014.01.004. Epub 2014 Feb 8. Blood Cells Mol Dis. 2014. PMID: 24512939 - Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y, Sun Y, Shen H, Ding L, Yang Z, Qiu H, Sun A, Chen S, Wu D. Xu Y, et al. Am J Hematol. 2015 Nov;90(11):992-7. doi: 10.1002/ajh.24135. Am J Hematol. 2015. PMID: 26223865 - Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Port M, et al. Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review. - Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B, Martelli MP. Falini B, et al. Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):90-7. doi: 10.1016/j.beha.2015.10.005. Epub 2015 Oct 22. Best Pract Res Clin Haematol. 2015. PMID: 26590764 Review.
Cited by
- Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia.
Tabatabaei T, Rezvany MR, Ghasemi B, Vafaei F, Zadeh MK, Zaker F, Salmaninejad A. Tabatabaei T, et al. Biomed Res Int. 2024 May 21;2024:9625043. doi: 10.1155/2024/9625043. eCollection 2024. Biomed Res Int. 2024. PMID: 38807916 Free PMC article. - CD7-positive leukemic blasts with DNMT3A mutations predict poor prognosis in patients with acute myeloid leukemia.
Bai Y, Sun X, Li M, Niu X, Cao W, Niu J, Xiao X, Chen Y, Sun K. Bai Y, et al. Front Oncol. 2024 Mar 21;14:1342998. doi: 10.3389/fonc.2024.1342998. eCollection 2024. Front Oncol. 2024. PMID: 38577341 Free PMC article. - The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia.
Chen X, Tian C, Hao Z, Pan L, Hong M, Wei W, Muyey DM, Wang H, Chen X. Chen X, et al. Cancer Med. 2023 May;12(9):10340-10350. doi: 10.1002/cam4.5764. Epub 2023 Mar 13. Cancer Med. 2023. PMID: 36912186 Free PMC article. - Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis.
Al-Bulushi F, Al-Riyami R, Al-Housni Z, Al-Abri B, Al-Khabori M. Al-Bulushi F, et al. Front Oncol. 2022 Nov 28;12:967657. doi: 10.3389/fonc.2022.967657. eCollection 2022. Front Oncol. 2022. PMID: 36518313 Free PMC article. - DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X, Zhong L, Dan W, Wang X, Zhang Z, Liu Z, Lu Y, Shao X, Zhou Z, Chen S, Liu B. Chu X, et al. Cell Commun Signal. 2022 Oct 27;20(1):168. doi: 10.1186/s12964-022-00978-1. Cell Commun Signal. 2022. PMID: 36303144 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous